IN8bio Inc Ordinary Shares INAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 9.85M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 18
- Website
- https://www.in8bio.com
Valuation
|
Metric
|
INAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.60 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INAB
|
|---|---|
Quick Ratio | 10.17 |
Current Ratio | 10.50 |
Interest Coverage | −288.57 |
Quick Ratio
INAB
Profitability
|
Metric
|
INAB
|
|---|---|
Return on Assets (Normalized) | −70.80% |
Return on Equity (Normalized) | −87.54% |
Return on Invested Capital (Normalized) | −76.65% |
Return on Assets
INAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?^#N>? | LOCK|W&z&W | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!b?&mz@ | LOCK|^#?B% | $70B | |||
| argenx SE ADR
ARGX
| LOCK|p!H#sD? | LOCK|t!K | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^k?tW< | LOCK|<QsY | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<dY&W%h | LOCK|<v& | $35B | |||
| Moderna Inc
MRNA
| LOCK|@>X@?gB | LOCK|S^W | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|mh$KkcJ | LOCK|XvB#N | $26B | |||
| Incyte Corp
INCY
| LOCK|$DQlCC | LOCK|WxT | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|GK<fS% | LOCK|sS | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|c??$ggv | LOCK|rLf | $18B |
United States